PINK
ESALY

Eisai Co Ltd ADR

Pharmaceuticals
Healthcare

Prices are adjusted according to historical splits.

Eisai Co Ltd ADR Stock Price

Vitals

Today's Low:
$13.6901
Today's High:
$13.98
Open Price:
$13.6901
52W Low:
$13.18
52W High:
$73.9
Prev. Close:
$13.84
Volume:
17964

Company Statistics

Market Cap.:
$17.64 billion
Book Value:
2886.461
Revenue TTM:
$752.50 billion
Operating Margin TTM:
-1.76%
Gross Profit TTM:
$581.40 billion
Profit Margin:
4.28%
Return on Assets TTM:
-0.69%
Return on Equity TTM:
3.86%

Company Profile

Eisai Co Ltd ADR had its IPO on 1961-09-01 under the ticker symbol ESALY.

The company operates in the Healthcare sector and Pharmaceuticals industry. Eisai Co Ltd ADR has a staff strength of 11,092 employees.

Stock update

Shares of Eisai Co Ltd ADR opened at $13.69 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $13.69 - $13.98, and closed at $13.9.

This is a +0.43% increase from the previous day's closing price.

A total volume of 17,964 shares were traded at the close of the day’s session.

In the last one week, shares of Eisai Co Ltd ADR have increased by +1.09%.

Eisai Co Ltd ADR's Key Ratios

Eisai Co Ltd ADR has a market cap of $17.64 billion, indicating a price to book ratio of 3.3725 and a price to sales ratio of 0.0262.

In the last 12-months Eisai Co Ltd ADR’s revenue was $752.50 billion with a gross profit of $581.40 billion and an EBITDA of $25.57 billion. The EBITDA ratio measures Eisai Co Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Eisai Co Ltd ADR’s operating margin was -1.76% while its return on assets stood at -0.69% with a return of equity of 3.86%.

In Q4, Eisai Co Ltd ADR’s quarterly earnings growth was a negative -11.4% while revenue growth was a positive 6.7%.

Eisai Co Ltd ADR’s PE and PEG Ratio

Forward PE
42.9185
Trailing PE
70.7012
PEG
0

Its diluted EPS in the last 12-months stands at $0.87 per share while it has a forward price to earnings multiple of 42.9185 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eisai Co Ltd ADR’s profitability.

Eisai Co Ltd ADR stock is trading at a EV to sales ratio of 0.025 and a EV to EBITDA ratio of 0.4445. Its price to sales ratio in the trailing 12-months stood at 0.0262.

Eisai Co Ltd ADR stock pays annual dividends of $160 per share, indicating a yield of 1.91% and a payout ratio of 128.46%.

Balance sheet and cash flow metrics

Total Assets
$1,251.07 billion
Total Liabilities
$313.68 billion
Operating Cash Flow
$0
Capital Expenditure
$7.14 billion
Dividend Payout Ratio
128.46%

Eisai Co Ltd ADR ended 2024 with $1,251.07 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1,251.07 billion while shareholder equity stood at $774.03 billion.

Eisai Co Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $313.68 billion in other current liabilities, 44986000000.00 in common stock, $504.95 billion in retained earnings and $207.49 billion in goodwill. Its cash balance stood at $268.00 billion and cash and short-term investments were $268.99 billion. The company’s total short-term debt was $65,200,000,000 while long-term debt stood at $84.92 billion.

Eisai Co Ltd ADR’s total current assets stands at $610.12 billion while long-term investments were $0 and short-term investments were $983.00 million. Its net receivables were $189.00 billion compared to accounts payable of $68.87 billion and inventory worth $120.86 billion.

In 2024, Eisai Co Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $7.14 billion.

Comparatively, Eisai Co Ltd ADR paid $1.28 in dividends in 2024.

Other key metrics

Current Trading Price
$13.9
52-Week High
$73.9
52-Week Low
$13.18
Analyst Target Price
$

Eisai Co Ltd ADR stock is currently trading at $13.9 per share. It touched a 52-week high of $73.9 and a 52-week low of $73.9. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $29.81 and 200-day moving average was $46.88 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 3.1% are held by institutions.

Frequently Asked Questions About Eisai Co Ltd ADR

The stock symbol (also called stock or share ticker) of Eisai Co Ltd ADR is ESALY

The IPO of Eisai Co Ltd ADR took place on 1961-09-01

Similar Industry Stocks (Pharmaceuticals)

Last Price
Chg
Chg%
$1.81
0.13
+7.74%
$100
-2.95
-2.87%
$1091.45
-36.85
-3.27%
$1.11
-0.02
-1.77%
$367.8
-10.9
-2.88%
$14.55
0.12
+0.83%
$965.7
-38.4
-3.82%
$0.23
0
+1.32%
$7.37
-0.32
-4.16%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Address

4-6-10, Koishikawa, Tokyo, Japan, 112-8088